CN118239847A - 具有神经保护作用的金刚烷胺硝酸酯化合物的制备方法 - Google Patents

具有神经保护作用的金刚烷胺硝酸酯化合物的制备方法 Download PDF

Info

Publication number
CN118239847A
CN118239847A CN202410514632.3A CN202410514632A CN118239847A CN 118239847 A CN118239847 A CN 118239847A CN 202410514632 A CN202410514632 A CN 202410514632A CN 118239847 A CN118239847 A CN 118239847A
Authority
CN
China
Prior art keywords
compound
structural formula
converted
follows
amantadine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410514632.3A
Other languages
English (en)
Chinese (zh)
Inventor
王玉强
孙业伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Magpie Pharmaceuticals Co Ltd
Original Assignee
Guangzhou Magpie Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Magpie Pharmaceuticals Co Ltd filed Critical Guangzhou Magpie Pharmaceuticals Co Ltd
Priority to CN202410514632.3A priority Critical patent/CN118239847A/zh
Publication of CN118239847A publication Critical patent/CN118239847A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
    • C07C209/76—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton by nitration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202410514632.3A 2014-05-29 2014-05-29 具有神经保护作用的金刚烷胺硝酸酯化合物的制备方法 Pending CN118239847A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410514632.3A CN118239847A (zh) 2014-05-29 2014-05-29 具有神经保护作用的金刚烷胺硝酸酯化合物的制备方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410235747.5A CN105294450B (zh) 2014-05-29 2014-05-29 具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用
CN202410514632.3A CN118239847A (zh) 2014-05-29 2014-05-29 具有神经保护作用的金刚烷胺硝酸酯化合物的制备方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201410235747.5A Division CN105294450B (zh) 2014-05-29 2014-05-29 具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用

Publications (1)

Publication Number Publication Date
CN118239847A true CN118239847A (zh) 2024-06-25

Family

ID=54698036

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202410514632.3A Pending CN118239847A (zh) 2014-05-29 2014-05-29 具有神经保护作用的金刚烷胺硝酸酯化合物的制备方法
CN202410514635.7A Pending CN118290279A (zh) 2014-05-29 2014-05-29 具有神经保护作用的金刚烷胺硝酸酯化合物的盐
CN201410235747.5A Active CN105294450B (zh) 2014-05-29 2014-05-29 具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202410514635.7A Pending CN118290279A (zh) 2014-05-29 2014-05-29 具有神经保护作用的金刚烷胺硝酸酯化合物的盐
CN201410235747.5A Active CN105294450B (zh) 2014-05-29 2014-05-29 具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用

Country Status (8)

Country Link
EP (1) EP3150574B1 (cg-RX-API-DMAC7.html)
JP (1) JP6639483B2 (cg-RX-API-DMAC7.html)
CN (3) CN118239847A (cg-RX-API-DMAC7.html)
AU (1) AU2015267968B2 (cg-RX-API-DMAC7.html)
CA (1) CA2950452C (cg-RX-API-DMAC7.html)
ES (1) ES2946987T3 (cg-RX-API-DMAC7.html)
IL (1) IL249242B (cg-RX-API-DMAC7.html)
WO (1) WO2015180485A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106397119A (zh) * 2016-04-11 2017-02-15 上海博康精细化工有限公司 一种1,3-金刚烷二乙醇的制备方法
KR101659055B1 (ko) * 2016-05-10 2016-09-23 박소정 에피갈로카테킨 갈레이트 및 3,1-아다만탄디아세트산을 함유하는 알쯔하이머성 치매 치료 및 예방용 약학조성물
CN106344551B (zh) * 2016-08-22 2020-07-28 广州喜鹊医药有限公司 氨基金刚烷单硝酸酯类化合物在制备预防和治疗疾病药物中的应用
CN107412211A (zh) * 2017-08-04 2017-12-01 佛山喜鹊医药有限公司 氨基金刚烷胺单硝酸酯类化合物眼用组合物及其制剂和应用
CA3081604A1 (en) * 2017-11-22 2019-05-31 Panorama Research, Inc. Aminoadamantyl nitrate compounds and their use to treat cns disorders
JP7296611B2 (ja) * 2018-08-03 2023-06-23 ビーエイチエヌ株式会社 一酸化窒素産生促進剤
CN109206317B (zh) * 2018-09-12 2021-07-09 青岛海蓝医药有限公司 一种金刚烷胺类硝酸酯衍生物的制备工艺
CN109172560B (zh) * 2018-10-15 2022-08-16 佛山喜鹊医药有限公司 氨基金刚烷硝酸酯类化合物或其药学上可接受的盐在预防和/或治疗肺部疾病中的应用
US20230218548A1 (en) * 2020-03-19 2023-07-13 Eumentis Therapeutics, Inc. Nitro-aminoadamantane compounds for the treatment of betacoronavirus infections
US20240130675A1 (en) * 2021-02-03 2024-04-25 The General Hospital Corporation Methods for Treating Autism Spectrum Disorder
CN116725997A (zh) * 2022-03-01 2023-09-12 广州喜鹊医药有限公司 氨基金刚烷单硝酸酯类化合物在制药领域中的应用
CN118271175A (zh) * 2022-12-31 2024-07-02 佛山喜鹊医药有限公司 新的金刚烷硝酸酯类化合物及其制备方法和用途
CN117224520A (zh) * 2023-11-01 2023-12-15 广州喜鹊医药有限公司 (3-氨基-5-乙基金刚烷-1-基)硝酸甲酯及其药学上可接受的盐的医药用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6444702B1 (en) * 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
MXPA03005130A (es) * 2000-12-07 2004-12-06 Neuromolecular Inc Metodos para tratar trastornos neurosiquiatricos con antagonistas del receptor del nmda.
CN1125033C (zh) * 2001-08-29 2003-10-22 中国科学院广州化学研究所 美金刚胺盐酸盐的合成方法
CA2426492C (en) * 2002-05-31 2006-10-03 H. Lundbeck A/S A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
CN1400205A (zh) * 2002-08-30 2003-03-05 中国科学院广州化学研究所 美金刚胺盐酸盐的制备方法
US20090088367A1 (en) * 2004-05-10 2009-04-02 Burnham Institute For Medical Research Treatment of Insulin Resistance/Metabolic Syndrome to Alleviate the Risks of Dementia
WO2007065036A2 (en) * 2005-12-02 2007-06-07 Neuromolecular Pharmaceuticals, Inc. Therapeutic conjugates and methods of using same
WO2014015047A1 (en) * 2012-07-17 2014-01-23 The General Hospital Corporation Compositions and methods to treat neurodegenerative diseases

Also Published As

Publication number Publication date
CN105294450A (zh) 2016-02-03
EP3150574A4 (en) 2017-11-22
ES2946987T3 (es) 2023-07-31
CA2950452C (en) 2020-03-31
CN118290279A (zh) 2024-07-05
IL249242A0 (en) 2017-02-28
IL249242B (en) 2020-03-31
EP3150574A1 (en) 2017-04-05
CN105294450B (zh) 2024-05-17
JP2017521482A (ja) 2017-08-03
AU2015267968A1 (en) 2016-12-15
EP3150574B1 (en) 2023-03-15
JP6639483B2 (ja) 2020-02-05
CA2950452A1 (en) 2015-12-03
AU2015267968B2 (en) 2018-05-17
WO2015180485A1 (zh) 2015-12-03

Similar Documents

Publication Publication Date Title
CN105294450B (zh) 具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用
FI95033B (fi) Menetelmä farmakologisesti aktiivisten 8-substituoitujen ksantiinijohdannaisten valmistamiseksi
CA1072112A (en) Benzylidene derivatives
CN103086935B (zh) 二苯硒醚、二苯硒亚砜、二苯硒砜类化合物及其用途
MXPA02008170A (es) Derivados de aminoadamantano como agentes terapeuticos.
US10214478B2 (en) Amantadine nitrate compounds with neural protective effect, and preparation and medical use thereof
SA519401049B1 (ar) مشتقات ثيوفين مكثفة مفيدة كمثبطات ناقل مشترك فوسفات يعتمد على أيون الصوديوم iiب
CN107163012A (zh) 一类3‑烃基‑5,6‑二氧取代苯酞化合物及其制备方法和用途
CA2949663C (en) Dipicolylamine derivatives and their pharmaceutical uses
WO2015055114A1 (zh) 二苯乙烷衍生物及其应用
CN111574533B (zh) 柠檬苦素a环开环胺化衍生物或其药学上可接受的盐、制备方法及用途
CN107522647B (zh) 含吲哚基团的α-氨基酰胺衍生物及其医药用途
CA3115162A1 (en) Compositions and methods for the treatment of parkinson's disease
JP2023538424A (ja) トリプトリドコンジュゲートおよびその使用
AU2020343737A1 (en) MAGL inhibitor, preparation method therefor and use thereof
CN106188209A (zh) 一种兼具抗肿瘤和抗肿瘤转移活性的二甲双胍偶联物及其应用
CN105732733A (zh) 基于葡萄糖的具有锁定功能的新型脑靶向前药
CN111518111B (zh) 脱氧柠檬苦素a环开环胺化衍生物或其药学上可接受的盐、制备方法及用途
WO2014195850A2 (en) Compositions and methods for the treatment of neurologic diseases and neurological disorders
CA2847971C (en) Stilbenoid compounds as inhibitors for squamous carcinoma and hepatoma and uses thereof
CN110684027B (zh) 右旋氟代巴拉苏酰胺及其衍生物的应用和该衍生物的制备方法
CN102241687A (zh) 抗缺血/再灌注损伤的药物
CN100551911C (zh) 具有含氮杂环修饰的多酚化合物及其应用
CN107056780B (zh) 硫辛酸-他克林类似基团异二联体及其治疗阿尔兹海默症的应用
CN107488179B (zh) 含桥环的咪唑醇衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination